Moreover, data from the literature indicate also that cachectic, treatment-naïve patients showed increased circulating levels of MCP-1, and the authors suggested that this molecule may be useful as a biomarker of cancer-associated cachexia [21, 22]. This evidence concerns the gene CCL2 and Cachexia.